NCT06268951
Recovery and Symptom Relief Following Percutaneous Ablation of Abdominal Wall Endometriosis
Enrolling by Invitation
Not specifiedAll AgesObservationalMayo ClinicInvestigator-initiated
~50 participants
Updated 2026-06-02 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Symptom severity due to abdominal wall endometriosis following ablation.
Measured over Baseline and intermittently over 24 months
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Thomas Atwell, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Undergoing ablation for abdominal wall endometriosis.
Exclusion
Decline to participate in research.
What this trial measures
- Symptom severity due to abdominal wall endometriosis following ablation.Baseline and intermittently over 24 months
Using the Endometriosis Health Profile - 30 survey, the impact of ablation on endometriosis-related symptoms will be quantified over time. A numerical rating scale will be used to quantify pain at the site of treated abdominal wall endometriosis.